Boston Scientific (BSX) Depreciation & Amortization (CF) (2020 - 2026)

Boston Scientific has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $355.0 million in Q2 2026.

• Depreciation & Amortization (CF) for Q2 2026 came in at $355.0 million, up 5.65% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.4 billion (up 7.45% YoY), and the FY2025 annual result was $1.4 billion, up 7.8% from the prior year.
• Depreciation & Amortization (CF) rose to $355.0 million in Q2 2026, from $351.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $365.0 million in Q4 2025 and troughed at $274.0 million in Q1 2022.
• A 5-year average of $315.3 million and a median of $308.5 million in 2024 frame the typical range for Depreciation & Amortization (CF).
• The widest annual swing landed in 2022, when Depreciation & Amortization (CF) increased 1.38%; it then climbed 11.76% in 2025.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $294.0 million in 2022, then grew by 6.46% to $313.0 million in 2023, then gained by 11.18% to $348.0 million in 2024, then rose by 4.89% to $365.0 million in 2025, then fell by 2.74% to $355.0 million in 2026.
• Per Business Quant data, the three most recent Depreciation & Amortization (CF) figures were $355.0 million in Q2 2026, $351.0 million in Q1 2026, and $365.0 million in Q4 2025.